Traders Speculate on IonQ Micron and Anduril as Next Potential US Government Equity Stakes Walmart Warns of Consumer Spending Slowdown as Rising Gas Prices Weigh on Shoppers AnduraX Advances Reusable Spaceplane Development with Critical Drop Test Softtech Engineers Stock at Key Breakout Level Market Eyes 470 Resistance SpaceX Starship V3 Test Flight Sparks Industry Assessment of Future Launch Market Chinas Humanoid Robot Push Musk Sees Biggest Competition as Nation Prepares Machines for Workforce JBS Q1 2026 Earnings EPS Falls Short of Estimates Amid Challenging Market Conditions i80 Gold Corp IAUX Q1 2026 Earnings Surprise EPS Beat as Loss Narrows PSTV Q1 2026 Earnings WiderthanExpected Loss Reflects Ongoing RD Investment Edgewell Personal Care Q1 2026 Earnings EPS Falls Short of Expectations Despite Stock Gain Creative Realities Inc Q1 2026 Earnings Significant EPS Miss Amidst Operational Challenges Eaton Vance Senior Income Trust EVF Holds Steady Near Support Amid Modest Decline Mohawk Industries MHK Edges Higher Amid Stabilizing Flooring Demand Fusemachines Inc FUSE Rallies 376 as It Rebounds from Key Support Level National Vision Holdings EYE Hovers Near Flat as Stock Tests Key Support Levels Apple Hospitality REIT APLE Faces Resistance Stock Slightly Lower on Modest Volume Homebuilder Stocks Show Potential Rebound as Technical Patterns Improve CRWD Q1 2026 Earnings EPS Slightly Misses Estimates Stock Drops 39 Autohome Inc ATHM Slips Slightly as Stock Hovers Near Key Support Levels Castle Biosciences Q1 2026 Earnings EPS Beat Slightly Narrower Loss Stock Rises 26 Mercury Achieves 52 Billion Valuation as Fintech Platform Deepens Focus on AI Startups ALOY Q1 2024 Earnings Significant EPS Miss Despite Positive Stock Reaction JPMorgan Banker Lorna Hajdini Countersues Accuser Over Sexual Assault Allegations Ray Dalio Reflects on 4000 Loan from Father After Early Career Mistake That Nearly Undid Bridgewater Associates Fold Holdings FLD Q1 2026 Earnings EPS Misses Estimates by Wide Margin as PreRevenue Company Reports Steep Losses Trevi Therapeutics Q1 2026 Earnings Narrowing Losses but Trial Failures Weigh on Sentiment